Screening for prostate cancer becomes more complex in men over the age of 70. The US Preventive Services Task Force (USPSTF) ...

Fresh from a European cancer conference that was all about antibody-drug conjugates (ADCs), GSK has turned to French biotech ...

NICE recommendation of darolutamide plus hormone therapy for metastatic prostate cancer offers around 6000 patients in ...

The National Institute for Health and Care Excellence (NICE) has recommended darolutamide in combination with androgen ...

NICE recommends Bayer’s Nubeqa® (darolutamide) plus androgen deprivation therapy as a treatment option for patients with hormone-sensitive metastatic prostate cancer Nubeqa® (darolutamide) plus ...

Patients with metastatic hormone-sensitive prostate cancer (mHSPC) lived significantly longer without disease progression ...

GSK has acquired the rights to Syndivia’s preclinical antibody drug conjugate (ADC), which is in development for prostate ...

Zoledronic acid reduced fracture risk by 27% in men with metastatic prostate cancer receiving ADT in the STAMPEDE trial. Patients with non-metastatic disease showed no significant fracture benefit ...

Sept. 18, 2025 -- About 1 in 8 men will face a prostate cancer diagnosis. Early-stage prostate cancer often has no symptoms—so how should men approach screening and advocacy? What disparities do Black ...

Men with recurrent prostate cancer following surgery or radiation therapy may now have a new chance to live longer. A massive ...

BERLIN — For men with high-risk biochemically recurrent prostate cancer, adding enzalutamide (Xtandi) to standard androgen ...